RT info:eu-repo/semantics/article
T1 Sensory gating deficits in the attenuated psychosis syndrome
A1 Shaikh, Madiha
A1 Dutt, Anirban
A1 Broome, Matthew R.
A1 Vozmediano, Alberto G.
A1 Ranlund, Siri
A1 Diez, Alvaro
A1 Caseiro, Olalla
A1 Lappin, Julia
A1 Amankwa, Susan
A1 Carletti, Francesco
A1 Fusar-Poli, Paolo
A1 Walshe, Muriel
A1 Hall, Mei-Hua
A1 Howes, Oliver
A1 Ellett, Lyn
A1 Murray, Robin M.
A1 McGuire, Philip
A1 Valmaggia, Lucia
A1 Bramon, Elvira
AB Background: Individuals with an "Attenuated Psychosis Syndrome" (APS) have a 20-40% chance of developing a psychotic disorder within two years; however it is difficult to predict which of them will become ill on the basis of their clinical symptoms alone. We examined whether P50 gating deficits could help to discriminate individuals with APS and also those who are particularly likely to make a transition to psychosis.Method: 36 cases meeting PACE (Personal Assessment and Crisis Evaluation) criteria for the APS, all free of antipsychotics, and 60 controls performed an auditory conditioning-testing experiment while their electroencephalogram was recorded. The P50 ratio and its C-T difference were compared between groups. Subjects received follow-up for up to 2 years to determine their clinical outcome.Results: The P50 ratio was significantly higher and C-T difference lower in the APS group compared to controls. Of the individuals with APS who completed the follow-up (n=36), nine (25%) developed psychosis. P50 ratio and the C-T difference did not significantly differ between those individuals who developed psychosis and those who did not within the APS group.Conclusion: P50 deficits appear to be associated with the pre-clinical phase of psychosis. However, due to the limitations of the study and its sample size, replication in an independent cohort is necessary, to clarify the role of P50 deficits in illness progression and whether this inexpensive and non-invasive EEG marker could be of clinical value in the prediction of psychosis outcomes amongst populations at risk.
SN 0920-9964
YR 2015
FD 2015
LK https://uvadoc.uva.es/handle/10324/66456
UL https://uvadoc.uva.es/handle/10324/66456
LA spa
NO Schizophrenia Research 161(2-3): 277-82
DS UVaDOC
RD 22-may-2024